Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy☆

Annals of Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles